BamSEC and AlphaSense Join Forces
Learn More

Chemokine Therapeutics Corp

Material Contracts Filter

EX-10.28
from 10KSB 3 pages Amendment to Employment Agreement
12/34/56
EX-10.24
from SB-2/A 15 pages Amended Employment Agreement
12/34/56
EX-10.26
from 10KSB ~20 pages Employment Agreement
12/34/56
EX-10.25
from 10KSB ~20 pages Employment Agreement
12/34/56
EX-10.24
from 10KSB ~5 pages Chemokine Therapeutics Corp. Indemnification Agreement
12/34/56
EX-10.23
from 10KSB ~50 pages Technical Enterprise Facility 3 Sub-Lease Article 1. - Basic Terms
12/34/56
EX-10.4
from 8-K 7 pages Partial Assignment of Sublease Gerald McGavin Building University of British Columbia
12/34/56
EX-10.3
from 8-K 5 pages Extension and Amendment of Sub-Lease Gerald McGavin Building University of British Columbia
12/34/56
EX-10.2
from 8-K 44 pages Sub-Lease Article 1 — Basic Terms and Specific Terms
12/34/56
EX-10.1
from 8-K 31 pages Article 1 Interpretation 1.1 Definitions. in This Agreement Unless Otherwise Expressly Provided: 1
12/34/56
EX-10.17
from 10QSB ~10 pages This Executive Services Agreement (“Agreement”) Is Made Effective the 28th Day of June, 2006. Jointly Between: Chemokine Therapeutics Corp. and Chemokine Therapeutics (Bc) Corp. 6190 Agronomy Road, Vancouver, Bc. Canada V6t 1z3 (“Company”) and Guy Ely, MD, (“Executive”) N.D. Life Sciences Corporation 2372 Valley Forest Way Oakville, Ontario Canada L6h 6w9 Executive Services Agreement
12/34/56
EX-10.22
from S-B/A 3 pages April 12, 2005 David Karp Chief Financial Officer Chemokine Therapeutics Corp. 2386 East Mall – Suite 208 Vancouver, Bc V6t 1z3 Canada via Campus Mail Dear Mr. Karp, Re: Amendment to License Agreement Between Ubc and Chemokine Therapeutics Corporation Dated September 22, 1999 (The “License”). This Letter Agreement Is to Amend the Subject of the License. the Parties Hereby Agree to Amend the License by Making the Following Changes: 1. Change Section 11.4(c) So That It Shall Now Read: (C) Commence Phase II Clinical Trials by December 31, 2005. the Licensee Covenants to Notify the University, in Writing, Within 15 Days of the Commencement of Phase II Clinical Trials;” 2. Change Section 12.2 So That It Shall Now Read: 12.2 the Licensee Will Complete and Deliver to Ubc
12/34/56
EX-10.21
from S-B/A 2 pages Preferred Stock and License Restructuring Agreement
12/34/56
EX-10
from 8-K 1 page Amended Employment Agreement
12/34/56
EX-10
from 8-K 1 page Amended Employment Agreement
12/34/56
EX-10.17
from SB-2/A ~10 pages Agent Warrant Agreement
12/34/56
EX-10.6
from SB-2/A ~20 pages Escrow Agreement
12/34/56
EX-10.16
from SB-2/A ~10 pages Form of Warrant Agreement Dated May 6, 2004
12/34/56
EX-10.15
from SB-2/A 1 page Lease Agreement Dated January 1, 2003
12/34/56
EX-10.15
from SB-2/A 1 page Lease Agreement Dated January 1, 2003
12/34/56